Fig. 1
Assure and ABCDai Benchmarking. A) Comparison of Caris Assure performance with published results of plasma-based genotyping22,23. The error bars indicate the 95% CIs and the asterisks (*) signify a significant difference of the TP/FN (for sensitivity) or TP/FP (for specificity) proportions between tests. Blue, Caris Assure; Red, Aggarwal; et al. (2018); Orange, Leighl et al. (2019); Green, Iams et al. (2024); Purple, Finkle et al. (2021); Brown, Bayle et al. (2022). B) Comparison of performance of ABCDai-MCED in Stage I and Stage II cancers against the published performance of a commercially available early detection product51. The error bars indicate the 95% CIs and the asterisks (*) signify a significant difference of the TP/FN proportions between tests. Blue, ABCDai-MCED; Red, Klein et al. (2021). C) Comparison of sensitivity, NPV, and specificity of ABCDai-M&M and a published tumor information naïve MRD product52. The error bars indicate the 95% CIs. Blue, ABCDai-M&M; Red, Nakamura et al. (2024). Abbreviations: BLAD, Bladder; CHOL, Cholangiocarcinoma; OV, Ovarian; SARC, Sarcoma; GAS, Gastric; CRC, Colorectal Cancer; UTER, Uterus; CERV, Cervical; KID, Kidney; PANC, Pancreatic; H&N, Head and Neck; BRCA, Breast Cancer; UT, Urinary Tract; MEL, Melanoma; PRAD, Prostate Adenocarcinoma; NSCLC, Non-small-cell Lung Cancer; THYR, Thyroid.
